At the time of writing, EyePoint Pharmaceuticals Inc [EYPT] stock is trading at $6.21, up 1.80%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The EYPT shares have gain 5.08% over the last week, with a monthly amount glided 5.25%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
EyePoint Pharmaceuticals Inc [NASDAQ: EYPT] stock has seen the most recent analyst activity on January 07, 2025, when Citigroup initiated its Buy rating and assigned the stock a price target of $33. On August 28, 2024, Jefferies initiated with a Buy rating and assigned a price target of $15 on the stock. JP Morgan started tracking the stock assigning a Overweight rating and suggested a price target of $35 on January 22, 2024. Mizuho initiated its recommendation with a Buy and recommended $20 as its price target on November 02, 2023. Robert W. Baird started tracking with a Outperform rating for this stock on April 21, 2023, and assigned it a price target of $33. In a note dated July 07, 2022, Chardan Capital Markets initiated an Buy rating and provided a target price of $21 on this stock.
For the past year, the stock price of EyePoint Pharmaceuticals Inc fluctuated between $3.91 and $13.98. Currently, Wall Street analysts expect the stock to reach $26 within the next 12 months. EyePoint Pharmaceuticals Inc [NASDAQ: EYPT] shares were valued at $6.21 at the most recent close of the market. An investor can expect a potential return of 318.68% based on the average EYPT price forecast.
Analyzing the EYPT fundamentals
According to EyePoint Pharmaceuticals Inc [NASDAQ:EYPT], the company’s sales were 56.04M for trailing twelve months, which represents an 109.29% jump. Gross Profit Margin for this corporation currently stands at 0.93% with Operating Profit Margin at -2.88%, Pretax Profit Margin comes in at -2.62%, and Net Profit Margin reading is -2.62%. To continue investigating profitability, this company’s Return on Assets is posted at -0.4, Equity is -0.54 and Total Capital is -0.5. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.08.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that EyePoint Pharmaceuticals Inc [NASDAQ:EYPT] has a current ratio of 7.85. As well, the Quick Ratio is 7.79, while the Cash Ratio is 2.04. Considering the valuation of this stock, the price to sales ratio is 7.63, the price to book ratio is 1.43.
Transactions by insiders
Recent insider trading involved Zaderej Karen L., Director, that happened on May 19 ’25 when 5000.0 shares were purchased. Director, Zaderej Karen L. completed a deal on May 16 ’25 to buy 5000.0 shares. Meanwhile, Director Zaderej Karen L. bought 5000.0 shares on May 15 ’25.
